JPRN-UMIN000009662已完成未知
The project to investigate mTOR inhibitor-induced immune modulation in subjects with renal cell cancer. - Japanese m-TOR Immune Modulation Trial(J-TORIM)
Departmentof Urology, Faculty of Life Sciences, Kumamoto University0 个研究点目标入组 30 人开始时间: 2013年1月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Patients with known hypersensitivity to temsirolimus or its metabolites (including sirolimus). 2.Female patients of childbearing potential (including male patients of planning to childbear ) and becoming pregnant. 3.Patients treated with m-TOR inhibitor or performed prior immunotherapy within 6 months. 4.Patients treated with systemic steroidal therapy or immunosuppressive drug. 5.Patients with brain metastasis. 6.Patients with active double cancers. 7.Patients with active infectious disease. 8.In addition, patients whom a doctor in judge unsuitable as a candidate patients of an examination.
研究者
相似试验
尚未招募
不适用
Efficacy of therapeutic drug monitoring of mTOR inhibitor (Everolimus) in patients with renal cell carcinomaMetastatic renal cell carcinomaJPRN-UMIN000011893Osaka General Medical Center20
进行中（未招募）
1 期
Phase II study of the mTOR-Inhibitor EVEROLIMUS asmaintenance therapy in patients aged over 60 years with MantleCell Lymphoma (MCL) after first, second, third or fourth linechemotherapyNew title since Protocol Version 4.0Phase II study of the mTOR-Inhibitor EVEROLIMUS asmaintenance therapy in patients aged over 60 years with MantleCell Lymphoma (MCL) after first, second, third or fourth linechemotherapy - CRAD001C2428Strategies to prolong remission duration in elderly patients with MCL are urgently needed. The effects of Rapamycin derivates on MCL cells in vitro and the evolving in vivo data support the further investigation of RAD001 in this incurable diseaseEUCTR2007-005116-12-DETechnical University of Munich
已完成
2 期
Evaluation of the molecular effects of metformin and improvement of symptoms in osteoarthritis patientsOsteoarthritis.Osteoarthritis of kneeIRCT20150202020908N2Shiraz University of Medical Sciences100
终止
1 期
Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer PatientsAdvanced CancersNCT00877773M.D. Anderson Cancer Center44
Unknown
2 期
Everolimus in Breast Cancer Patients After Pre-operative ChemotherapyBreast NeoplasmsNCT01088893Organisation for Oncology and Translational Research50